SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 4)*
NAME OF ISSUER: Gish Biomedical, Inc.
TITLE OF CLASS OF SECURITIES: Common Stock
CUSIP NUMBER: 376360103000
NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED TO
RECEIVE NOTICES AND COMMUNICATIONS:
Natalie I. Koether, Esq., Rosenman & Colin
211 Pennbrook Road, P. O. Box 97
Far Hills, New Jersey 07931 (908) 766-4101
DATE OF EVENT WHICH REQUIRES FILING: January 2, 2001
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1 (b)(3) or (4), check the following: ________
Check the following if a fee is being paid with the statement: (A fee
is not required only if the reporting person: (1) has a previous statement on
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover shall not be deemed to
be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934
("Act") or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).
(Continued on following pages)
<PAGE>
CUSIP NO.: 37636013000
1. NAME OF REPORTING PERSON: Asset Value Fund Limited Partnership
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
(a) (b) XX
3. [SEC USE ONLY]
4. SOURCE OF FUNDS: WC
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e): YES NO XX
6. CITIZENSHIP OR PLACE OF ORGANIZATION: New Jersey
7. SOLE VOTING POWER: 587,300
8. SHARED VOTING POWER:
9. SOLE DISPOSITIVE POWER: 587,300
10. SHARED DISPOSITIVE POWER:
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON: 587,300
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES: YES NO XX
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 16.35%
14. TYPE OF REPORTING PERSON: PN
<PAGE>
CUSIP NO.: 37636013000
1. NAME OF REPORTING PERSON: Howard F. Bovers
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
(a) (b) XX
3. [SEC USE ONLY]
4. SOURCE OF FUNDS: PF
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e): YES NO XX
6. CITIZENSHIP OR PLACE OF ORGANIZATION: U.S.A.
7. SOLE VOTING POWER: 0
8. SHARED VOTING POWER:
9. SOLE DISPOSITIVE POWER: 0
10. SHARED DISPOSITIVE POWER:
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON: 0
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES: YES NO XX
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 0%
14. TYPE OF REPORTING PERSON: IN
<PAGE>
Item 1. SECURITY AND ISSUER
On November 25, 1998, Asset Value Fund Limited Partnership ("Asset Value")
and Howard F. Bovers filed a Schedule 13D in connection with their respective
ownership of common stock, no par value per share ("Shares") of Gish Biomedical,
Inc., a California corporation (the "Company" or "Gish"). Gish's principal
executive offices are located at 2681 Kelvin Avenue, Irvine, California 92614.
The capitalized terms used in this Amendment, unless otherwise defined, shall
have the same meaning as in the original Schedule 13D.
This Amendment No. 4 is filed to report (1) that based on information and
belief, Mr. Bovers has sold all of his shares to unrelated party(ies) and
therefore no longer is reporting Share ownership with Asset Value and (2)
additional purchases of Shares by Asset Value.
Item 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
Since the date of the last filing, Asset Value has acquired 54,700 Shares
at an aggregate purchase price of $78,415.34, including brokerage commissions
where applicable. Asset Value purchased the Shares with its cash reserves. Since
the date of the last filing based on information and belief, Mr. Bovers has sold
all of his Shares.
Item 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) As of the close of business on January 2, 2001, Asset Value owned an
aggregate of 587,300 Shares, or approximately 16.35%.
(b) Asset Value has the sole power to vote and dispose of
587,300 Shares, or approximately 16.35%.
Percentage ownership is based upon the total Shares reported as outstanding
in the Company's Form 10-Q for the period ended September 30, 2000.
Item 7. MATERIAL TO BE FILED AS EXHIBITS.
Exhibit C - Transactions in Shares for the past 60 days
<PAGE>
SIGNATURE
---------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: January 3, 2001
ASSET VALUE FUND LIMITED PARTNERSHIP
By: Asset Value Management, Inc.
General Partner
By: /s/ John W. Galuchie, Jr.
--------------------------------
John W. Galuchie, Jr.
Treasurer and Secretary
<PAGE>
EXHIBIT C
Transactions in Shares for the Past 60 Days
NUMBER OF PRICE
DATE SHARES PURCHASED PER SHARE*
-------- -------------------------- ------------------
12/19/00 16,600 .93130
12/21/00 1,100 .84375
12/27/00 6,000 .84375
12/28/00 6,700 .8572
12/29/00 3,800 .84375
01/02/01 3,300 .84375
* Exclusive of brokerage commissions.
